NCT03085381已完成1 期
A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Systemic and local adverse events during the period of first dose vaccination to 30 days after last dose of vaccination
研究概览
简要总结
To evaluate the safety and primary immunogenicity of the quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (hansenula polymorpha) in Chinese female subjects aged 9-45 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 9 Years 至 45 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy females between, and including, 9 and 45 years of age at the time of enrolment
- •Be able to provide legal identification for the sake of recruitment
- •Be able to understand and sign informed consent form prior to enrollment and for subjects aged 9-17 years, they and their legal guardian(s) are supposed to understand and sign informed consent form together
- •Subjects who the investigator believes that they can and will comply with the protocol requirements
- •Subject must be not pregnant at the enrollment and agree to use adequate contraceptive precautions within 7 months or don't have pregnancy plan
排除标准
- •Fever or axillary temperature> 37.0℃ before vaccination
- •Previous vaccination against HPV, or planned administration/administration of a vaccine not foreseen by the study protocol within 30 days preceding first dose of vaccine; Planned to take part in other clinical research within 7 months after participating this study
- •Abnormal laboratory tests parameters
- •Administration of any whole blood, plasma or immunoglobulins products within 3 months preceding first vaccination
- •Interval between administration of the study vaccination and any attenuated live vaccine less than 14 days, and other vaccines less than 10 days
- •History of serious allergic disease requiring medical intervention (such as oral and throat swelling, difficulty breathing, hypotension or shock)
- •History of to adverse event to vaccine, or allergic to some food or drug
- •History of epilepsy, seizures or convulsions, or family history of mental illness
- •Subjects are immunocompromised or have been diagnosed as suffering from congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation (JRA), inflammatory bowel disease or other autoimmune diseases, administration of immunosuppressants with six months prior to the first vaccine dose.
- •Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy
- •Subject to severe hepatorenal disease, cardiovascular disease, hypertension, diabetes, malignant tumor, all kinds of infectious diseases and acute illness, or during chronic disease acute attack period
- •Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency, coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder
- •During menstrual period or acute disease period of onset
- •Breastfeeding, pregnancy (including pregnancy test positive), or planned to be pregnant within 7 months
- •Abnormal cervical cancer screening or subject to CIN or acuteness wet wart that relevant to HPV infection in the past two years
- •Planned to moveout of local before the end of the study or leave the local for a long time during the study period
- •Other unsuitable factors for the study judged by investigators
研究组 & 干预措施
Placebo
Placebo Comparator
Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
干预措施: Placebo (Biological)
HPV vaccine
Experimental
Subjects received 3 doses of HPV vaccine according to a 0, 2, 6-month schedule.
干预措施: HPV vaccine (Biological)
结局指标
主要结局
Systemic and local adverse events during the period of first dose vaccination to 30 days after last dose of vaccination
时间窗: 30 days after last dose of vaccination
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesCervical CancersCIN1CIN2CIN 3Invasive CarcinomaMild Dysplasia of VulvaModerate Dysplasia of VulvaVin IIIVaIN1VaIN2VaIN3Genital WartAISVulvar CancerVaginal CancerNCT03676101Shanghai Bovax Biotechnology Co., Ltd.90
Unknown
1 期
Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17Cervical CancerNCT02888418Beijing Chaoyang District Centre for Disease Control and Prevention135
Unknown
1 期
Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy FemalesHuman PapillomavirusNCT01548118Shanghai Zerun Biotechnology Co.,Ltd160
进行中（未招募）
3 期
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)Papillomavirus InfectionsNCT05285826Merck Sharp & Dohme LLC8,100
已完成
3 期
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)HPV InfectionsNCT00834106Merck Sharp & Dohme LLC3,006